Guardant Health推出针对实体瘤的全面免疫组化检测Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

动脉网

05-21

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test现已提供针对所有实体瘤关键生物标志物的完整IHC检测套件，包括c-MET，此外还有...

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537593518"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537593518\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537593518?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-05-21 20:52","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2537593518","market":"us","top_or_hot":-1,"title":"Guardant Health推出针对实体瘤的全面免疫组化检测Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors","media":"动脉网","content":"<div>\n<p>Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test现已提供针对所有实体瘤关键生物标志物的完整IHC检测套件，包括c-MET，此外还有...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052120541394fdf9dd&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardant Health推出针对实体瘤的全面免疫组化检测Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardant Health推出针对实体瘤的全面免疫组化检测Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-21 20:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052120541394fdf9dd&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test现已提供针对所有实体瘤关键生物标志物的完整IHC检测套件，包括c-MET，此外还有...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052120541394fdf9dd&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IHC","symbol_name":"独立控股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052120541394fdf9dd&s=b","article_id":"2537593518","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052120541394fdf9dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2537593518","pubTimestamp":1747831920,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test现已提供针对所有实体瘤关键生物标志物的完整IHC检测套件，包括c-MET，此外还有Guardant360组织多组学分析测试。IHC testing is a special staining process that detects specific proteins within a tissue sample, known as tumor biomarkers, that can be used to determine the characteristics of a tumor and identify the most appropriate targeted cancer therapy. The new Guardant IHC test suite provides comprehensive testing for key biomarkers in all solid tumors .IHC测试是一种特殊的染色过程，可检测组织样本中的特定蛋白质，即肿瘤生物标志物，这些标志物可用于确定肿瘤的特征并识别最合适的靶向癌症治疗方法。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IHC":"独立控股","BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4585":"ETF&股票定投概念","BK4162":"人寿与健康保险","GH":"Guardant Health Inc.","BK4588":"碎股","BK4196":"保健护理服务"},"translate_title":"Guardant Health launches comprehensive immunohistochemistry testing for solid tumors Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":0.9,"IHC":1},"content_text":"Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test现已提供针对所有实体瘤关键生物标志物的完整IHC检测套件，包括c-MET，此外还有Guardant360组织多组学分析测试。PALO ALTO, Calif.--(BUSINESS WIRE)--加利福尼亚州帕洛阿尔托--（BUSINESS WIRE）--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company’s portfolio of tumor molecular profiling tests. This new set of tests will help oncologists identify tumor subtypes and match cancer patients to the most effective targeted therapies..Guardant Health, Inc.（纳斯达克代码：GH），一家领先的精准肿瘤学公司，今日宣布在其肿瘤分子谱测试组合中新增一整套免疫组织化学（IHC）测试。这套新测试将帮助肿瘤科医生识别肿瘤亚型，并为癌症患者匹配最有效的靶向疗法。IHC testing is a special staining process that detects specific proteins within a tissue sample, known as tumor biomarkers, that can be used to determine the characteristics of a tumor and identify the most appropriate targeted cancer therapy. The new Guardant IHC test suite provides comprehensive testing for key biomarkers in all solid tumors (such as lung, breast, gastric and ovarian cancers).IHC测试是一种特殊的染色过程，可检测组织样本中的特定蛋白质，即肿瘤生物标志物，这些标志物可用于确定肿瘤的特征并识别最合适的靶向癌症治疗方法。新的Guardant IHC测试套件为所有实体瘤（如肺癌、乳腺癌、胃癌和卵巢癌）的关键生物标志物提供了全面的检测。This includes c-MET, the target of Emrelis™ (telisotuzumab vedotin-tllv), an antibody-drug conjugate recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of c-MET-expressing non-squamous non-small cell lung cancer (NSCLC)..这包括c-MET，即Emrelis™（telisotuzumab vedotin-tllv）的靶点，这是一种最近获得美国食品和药物管理局（FDA）批准用于治疗表达c-MET的非鳞状非小细胞肺癌（NSCLC）的抗体药物偶联物。“The information about tumor characteristics garnered from advanced IHC testing will complement the multidimensional insights we are currently providing to oncologists through our recently introduced Guardant360 Tissue multiomic tumor profiling test,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.“通过先进的IHC测试获得的肿瘤特征信息将对我们最近推出的Guardant360 Tissue多组学肿瘤分析测试所提供的多维度洞察形成补充，”Guardant Health董事长兼联合首席执行官Helmy Eltoukhy表示。“This expansion of our portfolio will allow us to offer cancer care teams more comprehensive tissue testing capabilities through a single source to help them make more informed decisions about therapy selection and optimize outcomes for their patients.”.“此次产品组合的扩展将使我们能够通过单一渠道为癌症治疗团队提供更全面的组织检测能力，帮助他们做出更明智的治疗选择决策，并优化患者的治疗效果。”The comprehensive IHC menu covers the following biomarkers: HER2, MMR, PD-L1, c-MET, ER, PR, Ki-67, CLDN18, and FOLR1.全面的IHC菜单涵盖以下生物标志物：HER2、MMR、PD-L1、c-MET、ER、PR、Ki-67、CLDN18和FOLR1。About Guardant Health关于Guardant HealthGuardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics.Guardant Health是一家领先的精准肿瘤学公司，专注于守护健康，让每个人拥有更多免受癌症困扰的时间。自2012年成立以来，Guardant通过其先进的血液和组织检测、真实世界数据以及人工智能分析，为疾病驱动因素提供关键见解，从而改变患者护理并加速新的癌症治疗方法的发展。Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on .Guardant测试有助于改善整个护理阶段的治疗效果，包括早期癌症筛查、早期癌症复发监测以及晚期癌症患者的治疗选择。欲了解更多信息，请访问guardanthealth.com并关注该公司。LinkedIn领英,，X (Twitter)X（推特）and和FacebookFacebook.。Forward-Looking Statements前瞻性声明This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements.本新闻稿包含联邦证券法意义上的前瞻性声明，包括关于 Guardant Health 液体活检测试或检测方法的潜在用途、价值、益处和优势的声明，这些声明涉及风险和不确定性，可能导致实际结果与这些前瞻性声明中表达的预期结果和期望存在重大差异。These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter.这些声明基于当前的预期、预测和假设，由于诸多因素，实际结果可能与这些声明存在重大差异。可能导致Guardant Health的财务和经营结果受到影响，并导致实际结果与本新闻稿中所作出的前瞻性声明存在重大差异的其他风险和不确定性，包括在其截至2024年12月31日年度的Form 10-K年报中“风险因素”和“管理层对财务状况及经营结果的讨论与分析”标题下以及其他部分讨论的内容，以及其后向证券交易委员会提交或递交的其他报告中所述内容。The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law.本新闻稿中的前瞻性陈述基于Guardant Health截至本日可获得的信息，Guardant Health拒绝承担更新任何前瞻性陈述的义务，以反映其预期的任何变化或事件、条件或情况的任何变化，除非法律要求。These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release..这些前瞻性陈述不应被视为代表Guardant Health在本新闻稿发布日期之后的任何日期的观点。Investor Contact:投资者联系方式：Zarak Khurshid扎拉克·赫尔希德investors@guardanthealth.com投资者@守护健康.comMedia Contact:媒体联系人：Michael Weist迈克尔·魏斯特press@guardanthealth.compress@guardanthealth.com+1 317-371-0035+1 317-371-0035Source: Guardant Health, Inc.来源：Guardant Health, Inc.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}